Etrasimod not checked
Pfizer · APD334 · PF-07915503
FollowEvery change as it happens, and a Monday email
Trials
3 active
18 in total · 5 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first”In the company’s words, NCT03950232 on ClinicalTrials.gov
- Tested for
- Ulcerative Colitis (2 trials), Colitis, Ulcerative
- Main trialPhase 3
- “The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 \[NCT03945188\] or APD334-302 \[NCT03996369\] or APD334-210 \[NCT04607837\]).”In the company’s words, NCT03950232 on ClinicalTrials.gov
- Other names
- APD334 · PF-07915503
Other drugs for Ulcerative Colitis
- TofacitinibPfizer · Phase 3
- UpadacitinibAbbVie · Phase 3
- RisankizumabAbbVie · Phase 3
- UstekinumabJohnson & Johnson (Janssen) · Phase 3
- IcotrokinraJohnson & Johnson (Janssen) · Phase 3
- ObefazimodAbivax S.A. · Phase 3
Coming up3
- 16 Jun 2029Phase 2 trial completes · ClinicalTrials.gov
- 19 Jun 2029Phase 3 trial completes · ClinicalTrials.gov
- 8 Sep 2030Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials18
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 19 Jun 2029 | An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Recruiting | 16 Jun 2029 | A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis | |
| Phase 2Recruiting | 8 Sep 2030 | A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis | |
| Phase 3Completed | 7 Dec 2021 | Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Completed | 8 Feb 2022 | Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis | |
| Phase 3Completed | 3 Aug 2022 | Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN) | |
| Phase 2/3Terminated | 29 Apr 2024 | A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection | |
| Phase 2/3Terminated | 23 Apr 2025 | A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease | |
| Phase 2Completed | 14 Feb 2018 | Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis | |
| Phase 2Terminated | 22 May 2018 | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum | |
| Phase 2Completed | 1 Nov 2018 | Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Terminated | 31 Jan 2019 | Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis | |
| Phase 2Completed | 9 Sep 2020 | A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis | |
| Phase 2Completed | 30 Sep 2022 | A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis | |
| Phase 2Completed | 7 Jun 2023 | Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata | |
| Phase 2Completed | 6 Oct 2023 | Etrasimod Dose-Ranging Versus Placebo as Induction Therapy Study in Adult Japanese Subjects With Moderately to Severely Active Ulcerative Colitis | |
| Phase 2Completed | 19 Jun 2024 | Etrasimod Versus Placebo for the Treatment of Moderately Active Ulcerative Colitis | |
| Phase 1Completed | 18 Sep 2026 | A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026